Matt Shair and Jim Porter (Nuvalent)
Months after emerging from stealth, Nuvalent follows up with $135M Series B — backed by some active players on the biotech IPO scene
When Matt Shair unveiled a $50 million Series A for his latest targeted therapy startup earlier this year, the Harvard professor was pleased with how capital efficient they managed to be.
“I think a lot of companies would take that $50 million and make some progress,” Shair, who had co-founded Infinity Pharma years ago, told Endpoints News then. “But we’ve taken that $50 million and with a small number of people, have two compounds headed into the clinic in three years, and have other programs in discovery phase.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
